Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
Primary nonresponse to infliximab in patients with ulcerative colitis (UC) is common. However, there are currently no effective biomarkers for this prediction. This study aimed to identify potential predictors for precision anti-tumor necrosis factor-alpha treatment in patients with UC. Four GPL570...
Saved in:
Main Authors: | Jixiang Zhang (Author), Xiaohan Wu (Author), Shuchun Wei (Author), Chuan Liu (Author), Xiaoli Wang (Author), Weiguo Dong (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
by: Lyu X, et al.
Published: (2023) -
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
by: Lu Liu, et al.
Published: (2022) -
Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
by: Jennifer C. C. deBruyn, et al.
Published: (2021) -
Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis
by: Mohamed G Fawaz, et al.
Published: (2022) -
Case Report: Unusual Cause of Fever in Ulcerative Colitis Treated with Infliximab
by: Sha S, et al.
Published: (2023)